NP137 is named as an intervention in 3 current clinical trials in our France register. None are recruiting at the moment. The most common phase is Phase 1. The sponsor with the most trials is University Hospital, Grenoble (1). The most-studied condition is Hepatocellular Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
NCT05605496 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Metastatic Solid Tumors
|
Phase 2 | Active, closed | Centre Leon Berard | France |
|
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
NCT04652076 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, Cervix Carcinoma
|
Phase 1/2 | Active, closed | NETRIS Pharma | France |
|
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
NCT05546879 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 1 | Active, closed | University Hospital, Grenoble | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| University Hospital, Grenoble | 1 |
| NETRIS Pharma | 1 |
| Centre Leon Berard | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 3 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our France register name NP137 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
University Hospital, Grenoble (1), NETRIS Pharma (1) and Centre Leon Berard (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how NP137 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NP137 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NP137 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.